April 23, 2025
Major Legal Victory for QuantifiCare: Düsseldorf Court Confirms Patent Infringement by Canfield’s Vectra H2 System.
QuantifiCare, a global leader in imaging solutions, has achieved a significant legal victory in its ongoing effort to defend its groundbreaking technology. The 4a Civil Chamber of the Düsseldorf Regional Court has ruled that Canfield Scientific’s VECTRA H2 device infringes QuantifiCare’s European patent No. EP 3 156 843 B1 which protects the LifeViz® Infinity system.
This decisive ruling affirms QuantifiCare’s status as a pioneer in 3D stereophotogrammetry and highlights the originality and strength of its intellectual property. In its judgment, the Court imposed multiple obligations and prohibitions on Canfield Scientific, including injunctions, mandatory disclosures, duties, financial compensation, and corrective measures related to the infringement of QuantifiCare’s patent.
“This judgment clearly confirms the strength of our intellectual property and highlights the originality of our innovations versus imitations. It reinforces our commitment to protecting our creations and the trust our partners place in our pioneering solutions” said Jean-Philippe Thirion, CEO of Quantificare.
Read more on JUVE Patent
About QuantifiCare’s European Patent 3 156 843:
A brief look back at the course of this legal dispute: QuantifiCare filed a French patent application on October 14, 2015, to protect essential aspects of the LifeViz® Infinity, the world’s first portable, all-in-one 3D imaging system specifically designed for the face, breast, and body applications. This system introduced a dual-distance imaging capability, enabling greater accuracy in clinical photography.
Within a year, the regional scope was extended to cover Europe and the US, laying the foundation for the successful launch of the LifeViz® Infinity system.
QuantifiCare’s position as a technological pioneer was reinforced by the grant of European Patent No. 3 156 843 by the European Patent Office on April 18, 2018. Following this grant, QuantifiCare initiated legal proceedings against Canfield Scientific alleging infringement of the afore-mentioned patent. In response to the infringement action, Canfield Scientific contested the validity of the patent in an attempt to nullify the infringement claims. This invalidity challenge was ultimately rejected: By decision rendered on July 23, 2024, the German Federal Supreme Court definitively upheld the German portion of European Patent No. 3 156 843, thereby confirming the enforceability of the patent.
The judgment by the 4a Civil Chamber of the Düsseldorf Regional Court confirming the infringement of QuantifiCare’s European patent EP 3 156 843 B1 by Canfield Scientific marks a key milestone in QuantifiCare’s ongoing efforts to protect core elements of its innovative LifeViz® Infinity technology.
In parallel, QuantifiCare has also initiated proceedings before the Unified Patent Court in 2024 in order to assert its rights in other Countries where the same patent applies, signaling and coordinated defense of its IP position.
About QuantifiCare’s LifeViz® Infinity:
The LifeViz® Infinity is the world’s first portable, all-in-one 3D imaging system designed for the face, breast, and body in medical, aesthetic and clinical trials. This groundbreaking device features a unique dual-distance repositioning system tailored for different imaging needs: one distance optimized for facial imaging and the other for breast and body imaging. The system utilizes two pairs of light beamers – crossing red beamers for short-distance (face) imaging and green beamers for long-distance (breast and body) imaging. Additionally, it includes a convenient switch to select the appropriate distance and adapt image intensity accordingly. These advanced features, along with the method of operating the device, are protected by QuantifiCare’s European patent 3 156 843.
Link to the press: